<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176525</url>
  </required_header>
  <id_info>
    <org_study_id>1241.2</org_study_id>
    <nct_id>NCT02176525</nct_id>
  </id_info>
  <brief_title>Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients</brief_title>
  <official_title>Safety, Antiviral Activity, and Pharmacokinetics of Multiple Oral Doses of BI 207127 NA Administered q8H for 5 Days as Monotherapy, a Randomised, Double-blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to investigate antiviral activity, safety and pharmacokinetics
      of 5 days of monotherapy with BI 207127 in HCV genotype 1 (GT1) infected patients. Both
      treatment-naïve patients and patients previously treated with peginterferon and ribavirin
      were included. In addition, the effect of study medication was examined in a group of
      patients with liver cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic Response (VR)</measure>
    <time_frame>Baseline (Visit 2_2 at planned time 5 minutes prior to first administration of trial drug), up to day 5</time_frame>
    <description>Virologic response was defined as a ≥ 1 log10 reduction in serum Hepatitis C virus (HCV) Ribonucleic acid (RNA) level from baseline at any time from the start of administration of treatment up to day 5. In this Outcome Measure the percentage of participants with virologic response is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Dependent Change From Baseline in Viral Load (VL)</measure>
    <time_frame>Baseline, up to day 7</time_frame>
    <description>Change of VL from baseline to day 7 is presented (VL at timepoint minus VL at baseline). Acronym used within the categories: planned time (PTM). The number of participants analysed displays the number of participants included in the analysis set whereas the number of participants for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>5 minutes (min) prior to the first dose of study medication and 30 minutes and 1:00, 2:00, 3:00, 4:00, 6:00, 7:55, 10:00, 12:00, 15:55, 18:00 hours (h) thereafter on day 1</time_frame>
    <description>Maximum measured concentration of Deleobuvir in plasma (Cmax) determined after the first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>5 minutes (min) prior to the first dose of study medication and 30 minutes and 1:00, 2:00, 3:00, 4:00, 6:00, 7:55, 10:00, 12:00, 15:55, 18:00 hours (h) thereafter on day 1</time_frame>
    <description>Measured concentration of Deleobuvir in plasma determined immediately before the second dose (Cmin). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>5 minutes (min) prior to the first dose of study medication and 30 minutes and 1:00, 2:00, 3:00, 4:00, 6:00, 7:55, 10:00, 12:00, 15:55, 18:00 hours (h) thereafter on day 1</time_frame>
    <description>Time from dosing to maximum measured concentration (tmax) of Deleobuvir determined after the first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-τ</measure>
    <time_frame>5 minutes (min) prior to the first dose of study medication and 30 minutes and 1:00, 2:00, 3:00, 4:00, 6:00, 7:55, 10:00, 12:00, 15:55, 18:00 hours (h) thereafter on day 1</time_frame>
    <description>Area under the concentration-time curve of Deleobuvir in plasma over the interval 0 hour (h) to the next dose of trial medication (AUC0-τ) measured after first administration of trial drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
    <description>The maximum measured concentration of Deleobuvir in plasma at steady state after the last dose of study drug (Cmax,ss).
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss</measure>
    <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
    <description>The minimum measured concentration of Deleobuvir in plasma at steady state (Cmin,ss).
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss</measure>
    <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
    <description>Time from dosing to the maximum measured concentration of Deleobuvir at steady state after the last dose of study drug (tmax,ss) more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss</measure>
    <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
    <description>Area under the concentration-time curve of Deleobuvir in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) measured after last dose of trial drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞,ss</measure>
    <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
    <description>Area under the concentration-time curve of Deleobuvir in plasma over the interval 0 hour (h) extrapolated to infinity at steady state (AUC0-∞,ss) measured after last administration of trial drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz,ss</measure>
    <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
    <description>Terminal rate of Deleobuvir constant in plasma at steady state (λz,ss) measured after last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss</measure>
    <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
    <description>Terminal half-life of Deleobuvir in plasma at steady state (t1/2,ss) measured after the last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss</measure>
    <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
    <description>Apparent clearance of Deleobuvir in plasma after oral administration at steady state (CL/F,ss) measured after the last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,ss</measure>
    <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
    <description>Apparent volume of Deleobuvir distribution during the terminal phase λz following an oral dose at steady state (Vz/F,ss) after the last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration Time Profiles</measure>
    <time_frame>up to day 7</time_frame>
    <description>Individual drug plasma concentrations of Deleobuvir after multiple oral administration. Within the categories PTM means planned time. The number of participants analysed displays the number of participants included in the analysis data set whereas the number of participants for each timepoint displays the number of participants with available data at that timepoint. Below the limit of quantification (BLQ) is abbreviated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Clinically Significant Changes in Vital Signs (Pulse Rate, Systolic and Diastolic Blood Pressure).</measure>
    <time_frame>Baseline, up to day 14</time_frame>
    <description>Number of patients with clinically significant changes in vital signs (pulse rate, systolic and diastolic blood pressure) presents the number of patients with an reported adverse event which has a symptom in changes in vital signs. Vascular disorders was identified as changes in vital signs. The number of participant with vascular disorders is presented in this outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Abnormal Findings in 12-lead ECG (Electrocardiogram)</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Number of patients with a new onset of an abnormal finding by central assessment are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Abnormal Changes in Laboratory Tests</measure>
    <time_frame>Baseline, up to day 14</time_frame>
    <description>Number of patients with abnormal changes in safety laboratory tests including urine protein diagnostics, and adrenocorticotropic hormone (ACTH) and cortisol measurements resulted in adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Number of patients with any adverse event (AE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Abnormal Findings in Physical Examination</measure>
    <time_frame>up to day 14</time_frame>
    <description>The number of patients with abnormal findings in physical examination presents the number of patients with any treatment-emergent adverse events in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Global Tolerability on a 4-point Scale</measure>
    <time_frame>day 6</time_frame>
    <description>The global tolerability was presented on a four item scale: good, satisfactory, not satisfactory and bad. Rating was done by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Visit 1, Visit 7</time_frame>
    <description>The body temperature will be presented as the mean values in visit 1 and visit 7. The number of participants analysed displays the number of participants included in the analysis set whereas the numbers for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>BI 207127 in patients with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple rising doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 207127 in patients without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple rising doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in patients without cirrhosis</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 NA</intervention_name>
    <arm_group_label>BI 207127 in patients with cirrhosis</arm_group_label>
    <arm_group_label>BI 207127 in patients without cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo in patients without cirrhosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults from 18 - 70 years

          -  Male OR female with documented hysterectomy OR menopausal female with last menstrual
             period at least 12 months prior to screening

          -  Written informed consent consistent with International Conference on
             Harmonization/Good Clinical Practice and local legislation given prior to any study
             procedures

          -  Chronic HCV infection demonstrated by positive HCV immunoglobulin G Antibody

          -  HCV genotype 1 which has to be confirmed by central laboratory test before Visit 2

          -  For non-cirrhotic cohorts: Liver biopsy obtained within the last 36 months consistent
             with HCV infection showing minimal to mild liver fibrosis and without cirrhosis (Ishak
             or Metavir grade ≤ 2). For cirrhotic cohorts, previous liver biopsy or Fibroscan
             consistent with liver cirrhosis performed at any time before screening

          -  HCV RNA load &gt; 100,000 IU RNA per ml serum at screening

        Exclusion Criteria:

          -  All fertile males not willing to use an adequate form of contraception (condom,
             sterilisation at least 6 months post operation) in case their partner is of
             childbearing potential and is not using an adequate form of contraception (hormonal
             contraceptives, oral or injectable/ implantable, intra-uterine device)

          -  Patients who have been treated with at least one dose of any HCV-polymerase inhibitor
             for acute or chronic hepatitis C infection

          -  Any other or additional plausible cause for chronic liver disease, including the
             presence of other viruses known or suspected to cause hepatitis

          -  Decompensated liver disease within past 12 months, as indicated by variceal bleeding,
             ascites, encephalopathy, Prothrombin or International Normalized Ratio (INR) prolonged
             to &gt;1.7 x upper limit of normal (ULN), serum bilirubin &gt; 2 mg/dl or albumin &lt; 3.5 g/dl
             (i.e. Child-Pugh grade B, score &gt; 7)

          -  For non-cirrhotic cohorts: Any previous liver biopsy consistent with cirrhosis. For
             cirrhotic cohorts: Any liver biopsy or fibroscan result from last 2 years excluding
             liver cirrhosis.

          -  Positive test for human immunodeficiency virus (HIV) or hepatitis B antigen at
             screening

          -  Current alcohol or drug abuse, or history of the same, within the past six (6) months.
             Exception: Occasional use of cannabis is not an exclusion criterion. The investigator
             must however instruct the patient that consumption of cannabis is not allowed during
             the treatment period.

          -  Any concurrent disease (cardiovascular, pulmonary, renal, haematological,
             neurological, psychiatric, immunologic, metabolic or endocrine dysfunction) if
             clinically significant based on the investigator's medical assessment at screening. A
             clinically significant disease is defined as one which in the opinion of the
             investigator may either put the patient at risk because of participation in the study
             or may influence the results of the study or the patient's ability to participate in
             the study. Exclusion is also necessary for any pre-existing cardiac abnormality by
             history.

          -  Clinically significant abnormalities at screening ECG, including but not limited to a
             QTc longer than 435 msec, Pulse Rate &gt; 240 msec at baseline and any bundle branch
             block pattern, but not necessarily non-specific T wave abnormalities

          -  History of malignancy (except for previously cured squamous cell or basal cell
             carcinoma)

          -  Patients treated with any interferon (IFN) (approved or investigational) or Peg-IFN
             and/or Ribavirin within 3 months prior to screening

          -  Planned or concurrent usage of any other pharmacological therapy including any
             antiviral therapy or vaccination from 7 days before treatment and during treatment

          -  Usage of any investigational drug within thirty (30) days prior to enrolment or 5
             halflives, whichever is longer; or the planned usage of an investigational drug during
             the course of the current study

          -  Known hypersensitivity to drugs or excipients

          -  Patients with any one of the following laboratory values at screening:

               -  Alanine transaminase (ALT) &gt; 3x ULN, local lab

               -  Aspartate aminotransferase (AST) &gt; 3x ULN, local lab

               -  Total bilirubin &gt; 1.5x ULN, local lab, unless predominantly conjugated and
                  reflecting Gilbert's disease

               -  Alkaline phosphatase &gt; 1.5x ULN, local lab

               -  Prothrombin time (INR) &gt; 1.5x ULN, central lab

               -  Creatinine &gt; 1x ULN, local lab

               -  Urine protein / creatinine ratio &gt; 0.3 g protein / g creatinine, central lab

               -  Alpha-1-microglobulin / creatinine in urine &gt; 1x ULN, central lab

               -  Platelet count &lt; 100,000 / mm3, central lab

               -  White Blood cell count &lt; 2000 cells/mm3, central lab

               -  Absolute neutrophile count &lt; 1500 cells, central lab

               -  Hemoglobin &lt; 12 g/dL, central lab

               -  For patients with liver cirrhosis:

                    -  ALT &gt; 5x ULN, local lab

                    -  AST &gt; 5x ULN, local lab

                    -  Platelet count &lt; 70,000 / mm3, central lab

          -  Patients with any clinically significant laboratory abnormalities based on the
             investigator's medical assessment at screening

          -  Positive urine test for drug abuse at screening

          -  Prior randomisation into this trial

          -  Inability to comply with the protocol

          -  Patients with ongoing or historical photosensitivity or recurrent rash

          -  Alpha fetoprotein value (AFP) &gt; 100 ng/ml; if AFP is &gt; 20 and ≤ 100 ng/ml, patients
             can be included if liver cancer is excluded by a current imaging study (i.e.
             ultrasound, computer tomography scan or magnetic resonance imaging)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related links</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <results_first_submitted>January 21, 2016</results_first_submitted>
  <results_first_submitted_qc>April 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2016</results_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>acronyms used in pre-assignment details: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP)</recruitment_details>
      <pre_assignment_details>Each patient participating in the trial (or the patient’s legally accepted representative) provided written informed consent according to ICH GCP and the regulatory and legal requirements of the participating country. All subjects were informed that they were free to withdraw their consent at any time during the study without penalty or prejudice.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Fibrosis</title>
          <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="P2">
          <title>DBV 100mg Fibrosis</title>
          <description>Deleobuvir (DBV) 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="P3">
          <title>DBV 200mg Fibrosis</title>
          <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="P4">
          <title>DBV 400mg Fibrosis</title>
          <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="P5">
          <title>DBV 400mg Cirrhosis</title>
          <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
        </group>
        <group group_id="P6">
          <title>DBV 600mg Cirrhosis</title>
          <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
        </group>
        <group group_id="P7">
          <title>DBV 800mg Fibrosis</title>
          <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="P8">
          <title>DBV 1200mg Fibrosis</title>
          <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15">15 subjects randomized, 14 subjects treated with at least one dose, 1 subject was not treated</participants>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="6">6 subjects randomized, 5 subjects treated with at least one dose, 1 subject was not treated</participants>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of study treatment, regardless of randomisation. Full analysis set (FAS) included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Fibrosis</title>
          <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="B2">
          <title>DBV 100mg Fibrosis</title>
          <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="B3">
          <title>DBV 200mg Fibrosis</title>
          <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="B4">
          <title>DBV 400mg Fibrosis</title>
          <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="B5">
          <title>DBV 400mg Cirrhosis</title>
          <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
        </group>
        <group group_id="B6">
          <title>DBV 600mg Cirrhosis</title>
          <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
        </group>
        <group group_id="B7">
          <title>DBV 800mg Fibrosis</title>
          <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="B8">
          <title>DBV 1200mg Fibrosis</title>
          <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="9"/>
            <count group_id="B8" value="10"/>
            <count group_id="B9" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="9.1"/>
                    <measurement group_id="B2" value="50.3" spread="11.9"/>
                    <measurement group_id="B3" value="51.7" spread="8.5"/>
                    <measurement group_id="B4" value="52.3" spread="8.7"/>
                    <measurement group_id="B5" value="55.4" spread="7.0"/>
                    <measurement group_id="B6" value="56.2" spread="8.1"/>
                    <measurement group_id="B7" value="47.3" spread="12.7"/>
                    <measurement group_id="B8" value="46.8" spread="8.6"/>
                    <measurement group_id="B9" value="50.24" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Virologic Response (VR)</title>
        <description>Virologic response was defined as a ≥ 1 log10 reduction in serum Hepatitis C virus (HCV) Ribonucleic acid (RNA) level from baseline at any time from the start of administration of treatment up to day 5. In this Outcome Measure the percentage of participants with virologic response is presented.</description>
        <time_frame>Baseline (Visit 2_2 at planned time 5 minutes prior to first administration of trial drug), up to day 5</time_frame>
        <population>The full analysis set (FAS) included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Fibrosis</title>
            <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O8">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VR)</title>
          <description>Virologic response was defined as a ≥ 1 log10 reduction in serum Hepatitis C virus (HCV) Ribonucleic acid (RNA) level from baseline at any time from the start of administration of treatment up to day 5. In this Outcome Measure the percentage of participants with virologic response is presented.</description>
          <population>The full analysis set (FAS) included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="4" upper_limit="40"/>
                    <measurement group_id="O2" value="22.2" lower_limit="7" upper_limit="56"/>
                    <measurement group_id="O3" value="55.6" lower_limit="26" upper_limit="81"/>
                    <measurement group_id="O4" value="88.9" lower_limit="55" upper_limit="97"/>
                    <measurement group_id="O5" value="87.5" lower_limit="52" upper_limit="97"/>
                    <measurement group_id="O6" value="100" lower_limit="61" upper_limit="100"/>
                    <measurement group_id="O7" value="88.9" lower_limit="55" upper_limit="97"/>
                    <measurement group_id="O8" value="100" lower_limit="76" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Dependent Change From Baseline in Viral Load (VL)</title>
        <description>Change of VL from baseline to day 7 is presented (VL at timepoint minus VL at baseline). Acronym used within the categories: planned time (PTM). The number of participants analysed displays the number of participants included in the analysis set whereas the number of participants for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline, up to day 7</time_frame>
        <population>The full analysis set (FAS) included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Fibrosis</title>
            <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O8">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Time Dependent Change From Baseline in Viral Load (VL)</title>
          <description>Change of VL from baseline to day 7 is presented (VL at timepoint minus VL at baseline). Acronym used within the categories: planned time (PTM). The number of participants analysed displays the number of participants included in the analysis set whereas the number of participants for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>The full analysis set (FAS) included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>log10 (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PTM 2:00 hours; N (per arm): 14/8/9/9/8/5/8/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.15"/>
                    <measurement group_id="O2" value="-0.03" spread="0.15"/>
                    <measurement group_id="O3" value="-0.06" spread="0.26"/>
                    <measurement group_id="O4" value="-0.13" spread="0.11"/>
                    <measurement group_id="O5" value="0.09" spread="0.10"/>
                    <measurement group_id="O6" value="-0.01" spread="0.16"/>
                    <measurement group_id="O7" value="0.05" spread="0.25"/>
                    <measurement group_id="O8" value="0.03" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 4:00 hours; N (per arm): 14/8/9/9/8/5/9/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.09"/>
                    <measurement group_id="O2" value="-0.02" spread="0.21"/>
                    <measurement group_id="O3" value="-0.16" spread="0.18"/>
                    <measurement group_id="O4" value="-0.25" spread="0.17"/>
                    <measurement group_id="O5" value="-0.07" spread="0.22"/>
                    <measurement group_id="O6" value="-0.03" spread="0.34"/>
                    <measurement group_id="O7" value="-0.26" spread="0.17"/>
                    <measurement group_id="O8" value="-0.15" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 7:55 hours; N (per arm): 14/8/9/9/8/5/9/9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.37"/>
                    <measurement group_id="O2" value="-0.33" spread="0.37"/>
                    <measurement group_id="O3" value="-0.53" spread="0.60"/>
                    <measurement group_id="O4" value="-0.96" spread="0.51"/>
                    <measurement group_id="O5" value="-0.90" spread="0.53"/>
                    <measurement group_id="O6" value="-1.05" spread="0.30"/>
                    <measurement group_id="O7" value="-1.41" spread="0.53"/>
                    <measurement group_id="O8" value="-1.11" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 10:00 hours; N (per arm): 14/8/9/9/8/5/9/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.19"/>
                    <measurement group_id="O2" value="-0.55" spread="0.49"/>
                    <measurement group_id="O3" value="-0.80" spread="0.59"/>
                    <measurement group_id="O4" value="-1.21" spread="0.60"/>
                    <measurement group_id="O5" value="-1.26" spread="0.53"/>
                    <measurement group_id="O6" value="-1.57" spread="0.56"/>
                    <measurement group_id="O7" value="-1.82" spread="0.59"/>
                    <measurement group_id="O8" value="-1.59" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 15:55 hours; N (per arm): 14/8/9/9/8/5/9/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.19"/>
                    <measurement group_id="O2" value="-0.53" spread="0.57"/>
                    <measurement group_id="O3" value="-0.96" spread="0.78"/>
                    <measurement group_id="O4" value="-1.66" spread="0.96"/>
                    <measurement group_id="O5" value="-1.89" spread="0.69"/>
                    <measurement group_id="O6" value="-2.30" spread="0.55"/>
                    <measurement group_id="O7" value="-2.40" spread="0.76"/>
                    <measurement group_id="O8" value="-2.31" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 18:00 hours; N (per arm): 14/8/9/9/8/5/9/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.18"/>
                    <measurement group_id="O2" value="-0.43" spread="0.55"/>
                    <measurement group_id="O3" value="-0.94" spread="0.69"/>
                    <measurement group_id="O4" value="-1.64" spread="0.96"/>
                    <measurement group_id="O5" value="-1.96" spread="0.69"/>
                    <measurement group_id="O6" value="-2.49" spread="0.57"/>
                    <measurement group_id="O7" value="-2.51" spread="0.86"/>
                    <measurement group_id="O8" value="-2.40" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 23:55 hours; N (per arm): 14/8/9/9/7/5/9/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.17"/>
                    <measurement group_id="O2" value="-0.53" spread="0.64"/>
                    <measurement group_id="O3" value="-0.93" spread="0.82"/>
                    <measurement group_id="O4" value="-1.67" spread="1.02"/>
                    <measurement group_id="O5" value="-2.03" spread="0.79"/>
                    <measurement group_id="O6" value="-2.75" spread="0.77"/>
                    <measurement group_id="O7" value="-2.46" spread="1.04"/>
                    <measurement group_id="O8" value="-2.45" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 47:55 hours; N (per arm): 13/7/9/9/7/5/9/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.18"/>
                    <measurement group_id="O2" value="-0.46" spread="0.65"/>
                    <measurement group_id="O3" value="-1.14" spread="1.26"/>
                    <measurement group_id="O4" value="-1.79" spread="1.25"/>
                    <measurement group_id="O5" value="-2.43" spread="0.88"/>
                    <measurement group_id="O6" value="-3.14" spread="0.67"/>
                    <measurement group_id="O7" value="-3.00" spread="1.14"/>
                    <measurement group_id="O8" value="-3.01" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 71:55 hours; N (per arm): 14/8/9/8/7/5/9/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.16"/>
                    <measurement group_id="O2" value="-0.50" spread="0.65"/>
                    <measurement group_id="O3" value="-1.16" spread="0.92"/>
                    <measurement group_id="O4" value="-1.84" spread="1.43"/>
                    <measurement group_id="O5" value="-2.50" spread="0.93"/>
                    <measurement group_id="O6" value="-3.17" spread="0.59"/>
                    <measurement group_id="O7" value="-3.02" spread="1.30"/>
                    <measurement group_id="O8" value="-2.97" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 95:55 hours; N (per arm): 14/8/9/8/7/5/9/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.27"/>
                    <measurement group_id="O2" value="-0.61" spread="0.65"/>
                    <measurement group_id="O3" value="-1.07" spread="0.94"/>
                    <measurement group_id="O4" value="-1.87" spread="1.33"/>
                    <measurement group_id="O5" value="-2.64" spread="1.19"/>
                    <measurement group_id="O6" value="-3.19" spread="0.56"/>
                    <measurement group_id="O7" value="-3.11" spread="1.23"/>
                    <measurement group_id="O8" value="-2.94" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 98:00 hours; N (per arm): 14/8/9/8/8/5/9/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.26"/>
                    <measurement group_id="O2" value="-0.66" spread="0.65"/>
                    <measurement group_id="O3" value="-1.08" spread="0.89"/>
                    <measurement group_id="O4" value="-1.93" spread="1.29"/>
                    <measurement group_id="O5" value="-2.64" spread="1.13"/>
                    <measurement group_id="O6" value="-3.13" spread="0.67"/>
                    <measurement group_id="O7" value="-3.17" spread="1.29"/>
                    <measurement group_id="O8" value="-3.01" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 100:00 hours; N (per arm): 14/8/9/8/7/5/8/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.24"/>
                    <measurement group_id="O2" value="-0.60" spread="0.58"/>
                    <measurement group_id="O3" value="-1.05" spread="0.80"/>
                    <measurement group_id="O4" value="-1.94" spread="1.24"/>
                    <measurement group_id="O5" value="-2.70" spread="1.23"/>
                    <measurement group_id="O6" value="-3.16" spread="0.83"/>
                    <measurement group_id="O7" value="-3.06" spread="1.40"/>
                    <measurement group_id="O8" value="-3.02" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 104:00 hours; N (per arm): 13/8/9/8/0/0/8/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.19"/>
                    <measurement group_id="O2" value="-0.77" spread="0.63"/>
                    <measurement group_id="O3" value="-1.08" spread="0.92"/>
                    <measurement group_id="O4" value="-1.96" spread="1.25"/>
                    <measurement group_id="O5" value="NA">N=0</measurement>
                    <measurement group_id="O6" value="NA">N=0</measurement>
                    <measurement group_id="O7" value="-3.27" spread="1.30"/>
                    <measurement group_id="O8" value="-3.11" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 108:00 hours; N (per arm): 14/8/9/8/8/5/8/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.20"/>
                    <measurement group_id="O2" value="-0.56" spread="0.53"/>
                    <measurement group_id="O3" value="-0.90" spread="1.01"/>
                    <measurement group_id="O4" value="-1.80" spread="1.25"/>
                    <measurement group_id="O5" value="-2.61" spread="1.17"/>
                    <measurement group_id="O6" value="-3.19" spread="0.58"/>
                    <measurement group_id="O7" value="-3.11" spread="1.20"/>
                    <measurement group_id="O8" value="-3.03" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 112:00 hours; N (per arm): 14/8/9/8/6/5/8/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.18"/>
                    <measurement group_id="O2" value="-0.56" spread="0.50"/>
                    <measurement group_id="O3" value="-0.87" spread="0.85"/>
                    <measurement group_id="O4" value="-1.64" spread="1.35"/>
                    <measurement group_id="O5" value="-2.95" spread="1.25"/>
                    <measurement group_id="O6" value="-3.12" spread="0.71"/>
                    <measurement group_id="O7" value="-2.98" spread="1.30"/>
                    <measurement group_id="O8" value="-2.91" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 120:00 hours; N (per arm): 14/8/9/8/6/5/8/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.50"/>
                    <measurement group_id="O2" value="-0.37" spread="0.41"/>
                    <measurement group_id="O3" value="-0.70" spread="0.68"/>
                    <measurement group_id="O4" value="-1.47" spread="1.29"/>
                    <measurement group_id="O5" value="-2.20" spread="1.46"/>
                    <measurement group_id="O6" value="-2.97" spread="1.13"/>
                    <measurement group_id="O7" value="-2.82" spread="1.40"/>
                    <measurement group_id="O8" value="-2.64" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 144:00 hours; N (per arm): 14/8/9/8/0/1/6/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.76"/>
                    <measurement group_id="O2" value="-0.19" spread="0.38"/>
                    <measurement group_id="O3" value="-0.40" spread="0.93"/>
                    <measurement group_id="O4" value="-0.76" spread="1.07"/>
                    <measurement group_id="O5" value="NA">N=0</measurement>
                    <measurement group_id="O6" value="-2.93">N=1</measurement>
                    <measurement group_id="O7" value="-1.88" spread="1.64"/>
                    <measurement group_id="O8" value="-1.61" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Maximum measured concentration of Deleobuvir in plasma (Cmax) determined after the first dose.</description>
        <time_frame>5 minutes (min) prior to the first dose of study medication and 30 minutes and 1:00, 2:00, 3:00, 4:00, 6:00, 7:55, 10:00, 12:00, 15:55, 18:00 hours (h) thereafter on day 1</time_frame>
        <population>The PK set (PKS) included all patients in the full analysis set (FAS) with evaluable PK data. FAS included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum measured concentration of Deleobuvir in plasma (Cmax) determined after the first dose.</description>
          <population>The PK set (PKS) included all patients in the full analysis set (FAS) with evaluable PK data. FAS included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>nanogram/millilitre (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" spread="75.0"/>
                    <measurement group_id="O2" value="656" spread="73.1"/>
                    <measurement group_id="O3" value="3500" spread="22.1"/>
                    <measurement group_id="O4" value="4060" spread="70.1"/>
                    <measurement group_id="O5" value="6760" spread="50.6"/>
                    <measurement group_id="O6" value="5730" spread="74.4"/>
                    <measurement group_id="O7" value="9570" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmin</title>
        <description>Measured concentration of Deleobuvir in plasma determined immediately before the second dose (Cmin). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
        <time_frame>5 minutes (min) prior to the first dose of study medication and 30 minutes and 1:00, 2:00, 3:00, 4:00, 6:00, 7:55, 10:00, 12:00, 15:55, 18:00 hours (h) thereafter on day 1</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin</title>
          <description>Measured concentration of Deleobuvir in plasma determined immediately before the second dose (Cmin). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
          <population>PKS</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" spread="83.1"/>
                    <measurement group_id="O2" value="210" spread="80.6"/>
                    <measurement group_id="O3" value="1190" spread="39.3"/>
                    <measurement group_id="O4" value="1520" spread="77.0"/>
                    <measurement group_id="O5" value="3470" spread="37.7"/>
                    <measurement group_id="O6" value="1800" spread="65.8"/>
                    <measurement group_id="O7" value="5090" spread="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Time from dosing to maximum measured concentration (tmax) of Deleobuvir determined after the first dose.</description>
        <time_frame>5 minutes (min) prior to the first dose of study medication and 30 minutes and 1:00, 2:00, 3:00, 4:00, 6:00, 7:55, 10:00, 12:00, 15:55, 18:00 hours (h) thereafter on day 1</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time from dosing to maximum measured concentration (tmax) of Deleobuvir determined after the first dose.</description>
          <population>PKS</population>
          <units>hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="4.17"/>
                    <measurement group_id="O2" value="3.03" lower_limit="2.03" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="6.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O6" value="4.00" lower_limit="2.83" upper_limit="6.00"/>
                    <measurement group_id="O7" value="6.00" lower_limit="4.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-τ</title>
        <description>Area under the concentration-time curve of Deleobuvir in plasma over the interval 0 hour (h) to the next dose of trial medication (AUC0-τ) measured after first administration of trial drug.</description>
        <time_frame>5 minutes (min) prior to the first dose of study medication and 30 minutes and 1:00, 2:00, 3:00, 4:00, 6:00, 7:55, 10:00, 12:00, 15:55, 18:00 hours (h) thereafter on day 1</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-τ</title>
          <description>Area under the concentration-time curve of Deleobuvir in plasma over the interval 0 hour (h) to the next dose of trial medication (AUC0-τ) measured after first administration of trial drug.</description>
          <population>PKS</population>
          <units>Nanogram*hours/millilitre (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1410" spread="77.9"/>
                    <measurement group_id="O2" value="2820" spread="66.6"/>
                    <measurement group_id="O3" value="15900" spread="27.3"/>
                    <measurement group_id="O4" value="18600" spread="62.7"/>
                    <measurement group_id="O5" value="29500" spread="49.4"/>
                    <measurement group_id="O6" value="23600" spread="69.5"/>
                    <measurement group_id="O7" value="42400" spread="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss</title>
        <description>The maximum measured concentration of Deleobuvir in plasma at steady state after the last dose of study drug (Cmax,ss).
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only)</description>
        <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss</title>
          <description>The maximum measured concentration of Deleobuvir in plasma at steady state after the last dose of study drug (Cmax,ss).
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only)</description>
          <population>PKS</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391" spread="67.8"/>
                    <measurement group_id="O2" value="910" spread="80.3"/>
                    <measurement group_id="O3" value="3780" spread="46.3"/>
                    <measurement group_id="O4" value="6780" spread="76.7"/>
                    <measurement group_id="O5" value="15400" spread="80.4"/>
                    <measurement group_id="O6" value="9030" spread="103.0"/>
                    <measurement group_id="O7" value="16500" spread="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmin,ss</title>
        <description>The minimum measured concentration of Deleobuvir in plasma at steady state (Cmin,ss).
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
        <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin,ss</title>
          <description>The minimum measured concentration of Deleobuvir in plasma at steady state (Cmin,ss).
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
          <population>PKS</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="98.5"/>
                    <measurement group_id="O2" value="201" spread="90.9"/>
                    <measurement group_id="O3" value="1150" spread="65.9"/>
                    <measurement group_id="O4" value="2340" spread="110.0"/>
                    <measurement group_id="O5" value="6920" spread="93.9"/>
                    <measurement group_id="O6" value="2100" spread="247.0"/>
                    <measurement group_id="O7" value="6630" spread="118.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax,ss</title>
        <description>Time from dosing to the maximum measured concentration of Deleobuvir at steady state after the last dose of study drug (tmax,ss) more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only)</description>
        <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax,ss</title>
          <description>Time from dosing to the maximum measured concentration of Deleobuvir at steady state after the last dose of study drug (tmax,ss) more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only)</description>
          <population>PKS</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="2.52" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="1.03" upper_limit="4.02"/>
                    <measurement group_id="O5" value="4.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O6" value="4.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="4.10" lower_limit="1.00" upper_limit="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCτ,ss</title>
        <description>Area under the concentration-time curve of Deleobuvir in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) measured after last dose of trial drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
        <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ,ss</title>
          <description>Area under the concentration-time curve of Deleobuvir in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) measured after last dose of trial drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
          <population>PKS</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1930" spread="79.0"/>
                    <measurement group_id="O2" value="4130" spread="79.1"/>
                    <measurement group_id="O3" value="17900" spread="37.1"/>
                    <measurement group_id="O4" value="36800" spread="82.7"/>
                    <measurement group_id="O5" value="86400" spread="78.1"/>
                    <measurement group_id="O6" value="43500" spread="118.0"/>
                    <measurement group_id="O7" value="88500" spread="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞,ss</title>
        <description>Area under the concentration-time curve of Deleobuvir in plasma over the interval 0 hour (h) extrapolated to infinity at steady state (AUC0-∞,ss) measured after last administration of trial drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
        <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞,ss</title>
          <description>Area under the concentration-time curve of Deleobuvir in plasma over the interval 0 hour (h) extrapolated to infinity at steady state (AUC0-∞,ss) measured after last administration of trial drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
          <population>PKS</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2560" spread="91.8"/>
                    <measurement group_id="O2" value="5420" spread="87.6"/>
                    <measurement group_id="O3" value="22800" spread="41.6"/>
                    <measurement group_id="O4" value="54300" spread="110.0"/>
                    <measurement group_id="O5" value="153000" spread="108.0"/>
                    <measurement group_id="O6" value="51700" spread="159.0"/>
                    <measurement group_id="O7" value="129000" spread="119.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>λz,ss</title>
        <description>Terminal rate of Deleobuvir constant in plasma at steady state (λz,ss) measured after last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
        <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>λz,ss</title>
          <description>Terminal rate of Deleobuvir constant in plasma at steady state (λz,ss) measured after last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
          <population>PKS</population>
          <units>1/h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.189" lower_limit="0.0976" upper_limit="0.264"/>
                    <measurement group_id="O2" value="0.180" lower_limit="0.111" upper_limit="0.322"/>
                    <measurement group_id="O3" value="0.131" lower_limit="0.110" upper_limit="0.186"/>
                    <measurement group_id="O4" value="0.117" lower_limit="0.0869" upper_limit="0.209"/>
                    <measurement group_id="O5" value="0.117" lower_limit="0.110" upper_limit="0.124"/>
                    <measurement group_id="O6" value="0.155" lower_limit="0.115" upper_limit="0.273"/>
                    <measurement group_id="O7" value="0.145" lower_limit="0.118" upper_limit="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2,ss</title>
        <description>Terminal half-life of Deleobuvir in plasma at steady state (t1/2,ss) measured after the last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
        <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2,ss</title>
          <description>Terminal half-life of Deleobuvir in plasma at steady state (t1/2,ss) measured after the last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
          <population>PKS</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" lower_limit="2.63" upper_limit="7.10"/>
                    <measurement group_id="O2" value="3.84" lower_limit="2.15" upper_limit="6.24"/>
                    <measurement group_id="O3" value="5.31" lower_limit="3.73" upper_limit="6.33"/>
                    <measurement group_id="O4" value="5.90" lower_limit="3.32" upper_limit="7.98"/>
                    <measurement group_id="O5" value="5.95" lower_limit="5.59" upper_limit="6.28"/>
                    <measurement group_id="O6" value="4.48" lower_limit="2.54" upper_limit="6.02"/>
                    <measurement group_id="O7" value="4.79" lower_limit="4.24" upper_limit="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F,ss</title>
        <description>Apparent clearance of Deleobuvir in plasma after oral administration at steady state (CL/F,ss) measured after the last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
        <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F,ss</title>
          <description>Apparent clearance of Deleobuvir in plasma after oral administration at steady state (CL/F,ss) measured after the last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
          <population>PKS</population>
          <units>Millilitre per minute (mL/min)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="865" spread="79.0"/>
                    <measurement group_id="O2" value="806" spread="79.1"/>
                    <measurement group_id="O3" value="372" spread="37.1"/>
                    <measurement group_id="O4" value="181" spread="82.7"/>
                    <measurement group_id="O5" value="116" spread="78.1"/>
                    <measurement group_id="O6" value="319" spread="132.0"/>
                    <measurement group_id="O7" value="226" spread="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F,ss</title>
        <description>Apparent volume of Deleobuvir distribution during the terminal phase λz following an oral dose at steady state (Vz/F,ss) after the last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
        <time_frame>5 min prior to the first dose of study medication of Day 5; 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00, 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h thereafter</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F,ss</title>
          <description>Apparent volume of Deleobuvir distribution during the terminal phase λz following an oral dose at steady state (Vz/F,ss) after the last dose of study drug.
more detailed time frame information: 5 minutes (min) prior to the first dose of study medication of Day 5 (-0:05) and 0:30, 1:00, 2:00, 3:00*, 4:00, 6:00, 8:00*, 10:00, 12:00, 16:00, 24:00, 48:00 h thereafter; Assigned to the planned time points 95:55, 96:30, 97:00, 98:00 99:00*, 100:00, 102:00, 104:00*, 106:00, 108:00, 112:00, 120:00, 144:00 h (*At these time points, in patients with cirrhosis only). The number of participants analysed displays the number of participants with available data at the timepoints of interest.</description>
          <population>PKS</population>
          <units>Litre (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279" spread="53.1"/>
                    <measurement group_id="O2" value="254" spread="49.8"/>
                    <measurement group_id="O3" value="164" spread="41.4"/>
                    <measurement group_id="O4" value="83.9" spread="58.2"/>
                    <measurement group_id="O5" value="59.7" spread="72.8"/>
                    <measurement group_id="O6" value="110" spread="108.0"/>
                    <measurement group_id="O7" value="96.8" spread="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration Time Profiles</title>
        <description>Individual drug plasma concentrations of Deleobuvir after multiple oral administration. Within the categories PTM means planned time. The number of participants analysed displays the number of participants included in the analysis data set whereas the number of participants for each timepoint displays the number of participants with available data at that timepoint. Below the limit of quantification (BLQ) is abbreviated.</description>
        <time_frame>up to day 7</time_frame>
        <population>The full analysis set (FAS) included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration Time Profiles</title>
          <description>Individual drug plasma concentrations of Deleobuvir after multiple oral administration. Within the categories PTM means planned time. The number of participants analysed displays the number of participants included in the analysis data set whereas the number of participants for each timepoint displays the number of participants with available data at that timepoint. Below the limit of quantification (BLQ) is abbreviated.</description>
          <population>The full analysis set (FAS) included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PTM 0.5 hours; N(per Arm)=6/6/7/8/3/5/9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6" spread="328.0"/>
                    <measurement group_id="O2" value="15.1" spread="57.7"/>
                    <measurement group_id="O3" value="163" spread="214.0"/>
                    <measurement group_id="O4" value="45.4" spread="632.0"/>
                    <measurement group_id="O5" value="NA">2 of 5 samples BLQ, no descriptive statistics calculated</measurement>
                    <measurement group_id="O6" value="NA">4 of 9 samples BLQ, no descriptive statistics calculated</measurement>
                    <measurement group_id="O7" value="124" spread="1250.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 1 hour; N(per Arm)=7/9/9/8/5/8/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" spread="111.0"/>
                    <measurement group_id="O2" value="53.0" spread="387.0"/>
                    <measurement group_id="O3" value="427" spread="569.0"/>
                    <measurement group_id="O4" value="597" spread="168.0"/>
                    <measurement group_id="O5" value="177" spread="258.0"/>
                    <measurement group_id="O6" value="519" spread="570.0"/>
                    <measurement group_id="O7" value="647" spread="275.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 2 hours; N(per Arm)=9/9/9/8/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208" spread="199.0"/>
                    <measurement group_id="O2" value="246" spread="133.0"/>
                    <measurement group_id="O3" value="2290" spread="70.8"/>
                    <measurement group_id="O4" value="1720" spread="62.4"/>
                    <measurement group_id="O5" value="1390" spread="112.0"/>
                    <measurement group_id="O6" value="1650" spread="240.0"/>
                    <measurement group_id="O7" value="1780" spread="208.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 3 hours; N(per Arm)=9/9/9/8/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" spread="213.0"/>
                    <measurement group_id="O2" value="476" spread="74.9"/>
                    <measurement group_id="O3" value="2830" spread="41.8"/>
                    <measurement group_id="O4" value="2950" spread="50.1"/>
                    <measurement group_id="O5" value="3330" spread="89.9"/>
                    <measurement group_id="O6" value="3750" spread="106.0"/>
                    <measurement group_id="O7" value="4330" spread="110.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 4 hours; N(per Arm)=9/9/9/8/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274" spread="70.0"/>
                    <measurement group_id="O2" value="574" spread="73.8"/>
                    <measurement group_id="O3" value="2800" spread="35.6"/>
                    <measurement group_id="O4" value="3740" spread="70.4"/>
                    <measurement group_id="O5" value="5060" spread="83.2"/>
                    <measurement group_id="O6" value="4920" spread="78.0"/>
                    <measurement group_id="O7" value="6930" spread="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 6 hours; N(per Arm)=9/8/9/8/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181" spread="69.5"/>
                    <measurement group_id="O2" value="377" spread="57.6"/>
                    <measurement group_id="O3" value="2030" spread="42.9"/>
                    <measurement group_id="O4" value="2760" spread="89.7"/>
                    <measurement group_id="O5" value="6250" spread="57.4"/>
                    <measurement group_id="O6" value="3350" spread="75.0"/>
                    <measurement group_id="O7" value="8890" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 7.917 hours; N(per Arm)=8/8/9/8/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" spread="83.1"/>
                    <measurement group_id="O2" value="210" spread="80.6"/>
                    <measurement group_id="O3" value="1190" spread="39.3"/>
                    <measurement group_id="O4" value="1520" spread="77.0"/>
                    <measurement group_id="O5" value="3470" spread="37.7"/>
                    <measurement group_id="O6" value="1800" spread="65.8"/>
                    <measurement group_id="O7" value="5090" spread="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 10 hours; N(per Arm)=9/9/9/8/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282" spread="88.7"/>
                    <measurement group_id="O2" value="646" spread="170.0"/>
                    <measurement group_id="O3" value="4170" spread="93.7"/>
                    <measurement group_id="O4" value="2580" spread="79.7"/>
                    <measurement group_id="O5" value="5770" spread="88.6"/>
                    <measurement group_id="O6" value="4120" spread="75.4"/>
                    <measurement group_id="O7" value="9720" spread="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 12 hours; N(per Arm)=9/9/9/8/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161" spread="66.2"/>
                    <measurement group_id="O2" value="769" spread="92.8"/>
                    <measurement group_id="O3" value="3300" spread="31.5"/>
                    <measurement group_id="O4" value="3500" spread="74.8"/>
                    <measurement group_id="O5" value="7340" spread="49.6"/>
                    <measurement group_id="O6" value="7290" spread="48.2"/>
                    <measurement group_id="O7" value="12700" spread="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 15.917 hours; N(per Arm)=9/9/9/7/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" spread="101.0"/>
                    <measurement group_id="O2" value="222" spread="90.5"/>
                    <measurement group_id="O3" value="1180" spread="32.7"/>
                    <measurement group_id="O4" value="1600" spread="76.1"/>
                    <measurement group_id="O5" value="5230" spread="49.2"/>
                    <measurement group_id="O6" value="2220" spread="96.1"/>
                    <measurement group_id="O7" value="5120" spread="112.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 18 hours; N(per Arm)=9/9/9/8/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265" spread="69.7"/>
                    <measurement group_id="O2" value="379" spread="155.0"/>
                    <measurement group_id="O3" value="2520" spread="82.6"/>
                    <measurement group_id="O4" value="2870" spread="97.5"/>
                    <measurement group_id="O5" value="5340" spread="67.9"/>
                    <measurement group_id="O6" value="3060" spread="165.0"/>
                    <measurement group_id="O7" value="8100" spread="108.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 23.917 hours; N(per Arm)=9/9/9/7/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" spread="98.1"/>
                    <measurement group_id="O2" value="531" spread="78.1"/>
                    <measurement group_id="O3" value="2290" spread="48.8"/>
                    <measurement group_id="O4" value="3570" spread="113.0"/>
                    <measurement group_id="O5" value="7690" spread="61.5"/>
                    <measurement group_id="O6" value="4840" spread="91.4"/>
                    <measurement group_id="O7" value="13800" spread="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 47.917 hours; N(per Arm)=9/9/9/7/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154" spread="81.4"/>
                    <measurement group_id="O2" value="403" spread="96.6"/>
                    <measurement group_id="O3" value="2200" spread="32.6"/>
                    <measurement group_id="O4" value="3490" spread="119.0"/>
                    <measurement group_id="O5" value="9200" spread="83.6"/>
                    <measurement group_id="O6" value="4680" spread="157.0"/>
                    <measurement group_id="O7" value="12000" spread="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 71.917 hours; N(per Arm)=9/9/8/7/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" spread="98.0"/>
                    <measurement group_id="O2" value="378" spread="70.7"/>
                    <measurement group_id="O3" value="1670" spread="40.6"/>
                    <measurement group_id="O4" value="3420" spread="90.0"/>
                    <measurement group_id="O5" value="11500" spread="77.2"/>
                    <measurement group_id="O6" value="3170" spread="219.0"/>
                    <measurement group_id="O7" value="9440" spread="202.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 95.917 hours; N(per Arm)=9/9/8/7/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" spread="93.7"/>
                    <measurement group_id="O2" value="383" spread="88.7"/>
                    <measurement group_id="O3" value="1880" spread="34.0"/>
                    <measurement group_id="O4" value="2820" spread="86.8"/>
                    <measurement group_id="O5" value="5600" spread="192.0"/>
                    <measurement group_id="O6" value="3120" spread="224.0"/>
                    <measurement group_id="O7" value="7820" spread="133.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 96.5 hours; N(per Arm)=9/9/8/7/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149" spread="90.6"/>
                    <measurement group_id="O2" value="366" spread="84.7"/>
                    <measurement group_id="O3" value="1830" spread="51.1"/>
                    <measurement group_id="O4" value="3220" spread="85.0"/>
                    <measurement group_id="O5" value="8360" spread="92.7"/>
                    <measurement group_id="O6" value="3330" spread="181.0"/>
                    <measurement group_id="O7" value="7840" spread="114.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 97 hours; N(per Arm)=9/9/8/7/5/9/9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209" spread="88.4"/>
                    <measurement group_id="O2" value="427" spread="86.0"/>
                    <measurement group_id="O3" value="2400" spread="56.7"/>
                    <measurement group_id="O4" value="3610" spread="76.3"/>
                    <measurement group_id="O5" value="8510" spread="73.9"/>
                    <measurement group_id="O6" value="4350" spread="142.0"/>
                    <measurement group_id="O7" value="9460" spread="118.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 98 hours; N(per Arm)=9/9/8/7/5/9/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313" spread="64.3"/>
                    <measurement group_id="O2" value="503" spread="105.0"/>
                    <measurement group_id="O3" value="2760" spread="49.7"/>
                    <measurement group_id="O4" value="4620" spread="77.0"/>
                    <measurement group_id="O5" value="10000" spread="74.3"/>
                    <measurement group_id="O6" value="7390" spread="118.0"/>
                    <measurement group_id="O7" value="11400" spread="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 99 hours; N(per Arm)=9/9/8/7/5/8/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300" spread="70.4"/>
                    <measurement group_id="O2" value="565" spread="108.0"/>
                    <measurement group_id="O3" value="2820" spread="37.2"/>
                    <measurement group_id="O4" value="5120" spread="93.5"/>
                    <measurement group_id="O5" value="11200" spread="79.5"/>
                    <measurement group_id="O6" value="7990" spread="94.2"/>
                    <measurement group_id="O7" value="12200" spread="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 100 hours; N(per Arm)=9/9/8/7/5/8/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329" spread="86.9"/>
                    <measurement group_id="O2" value="658" spread="109.0"/>
                    <measurement group_id="O3" value="2790" spread="50.2"/>
                    <measurement group_id="O4" value="6210" spread="89.9"/>
                    <measurement group_id="O5" value="14800" spread="86.7"/>
                    <measurement group_id="O6" value="7740" spread="107.0"/>
                    <measurement group_id="O7" value="14000" spread="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 102 hours; N(per Arm)=9/9/8/7/5/8/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199" spread="92.7"/>
                    <measurement group_id="O2" value="492" spread="99.4"/>
                    <measurement group_id="O3" value="1630" spread="70.6"/>
                    <measurement group_id="O4" value="4600" spread="102.0"/>
                    <measurement group_id="O5" value="11400" spread="76.6"/>
                    <measurement group_id="O6" value="4450" spread="144.0"/>
                    <measurement group_id="O7" value="11200" spread="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 104 hours; N(per Arm)=9/9/8/7/5/7/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" spread="113.0"/>
                    <measurement group_id="O2" value="254" spread="109.0"/>
                    <measurement group_id="O3" value="867" spread="73.1"/>
                    <measurement group_id="O4" value="2710" spread="119.0"/>
                    <measurement group_id="O5" value="7450" spread="91.5"/>
                    <measurement group_id="O6" value="2230" spread="222.0"/>
                    <measurement group_id="O7" value="6830" spread="150.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 106 hours; N(per Arm)=9/9/8/7/5/7/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="121.0"/>
                    <measurement group_id="O2" value="158" spread="115.0"/>
                    <measurement group_id="O3" value="553" spread="74.8"/>
                    <measurement group_id="O4" value="1720" spread="153.0"/>
                    <measurement group_id="O5" value="5260" spread="115.0"/>
                    <measurement group_id="O6" value="1200" spread="316.0"/>
                    <measurement group_id="O7" value="4370" spread="190.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 108 hours; N(per Arm)=9/9/8/7/5/7/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="136.0"/>
                    <measurement group_id="O2" value="92.7" spread="136.0"/>
                    <measurement group_id="O3" value="321" spread="79.0"/>
                    <measurement group_id="O4" value="1160" spread="171.0"/>
                    <measurement group_id="O5" value="4040" spread="120.0"/>
                    <measurement group_id="O6" value="681" spread="403.0"/>
                    <measurement group_id="O7" value="2780" spread="314.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 112 hours; N(per Arm)=9/9/8/7/5/7/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="138.0"/>
                    <measurement group_id="O2" value="39.9" spread="157.0"/>
                    <measurement group_id="O3" value="153" spread="82.6"/>
                    <measurement group_id="O4" value="553" spread="211.0"/>
                    <measurement group_id="O5" value="1890" spread="130.0"/>
                    <measurement group_id="O6" value="239" spread="436.0"/>
                    <measurement group_id="O7" value="1110" spread="444.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 120 hours; N(per Arm)= 5/6/8/ 7/5/7/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">4 of 9 samples below limit of quantification (BLQ). 5 values were reportable (5 of 9 = total N of 55.6%), no descriptive statistics calculated. A total N of 66.7 % (2/3) of reportable values is needed.</measurement>
                    <measurement group_id="O2" value="20.2" spread="126.0"/>
                    <measurement group_id="O3" value="59.0" spread="75.9"/>
                    <measurement group_id="O4" value="219" spread="269.0"/>
                    <measurement group_id="O5" value="699" spread="185.0"/>
                    <measurement group_id="O6" value="67.2" spread="384.0"/>
                    <measurement group_id="O7" value="316" spread="512.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTM 144 hours; N(per Arm)= 1/1/5/ 5/5/4/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">8 of 9 samples BLQ, no descriptive statistics calculated</measurement>
                    <measurement group_id="O2" value="NA">8 of 9 samples BLQ, no descriptive statistics calculated</measurement>
                    <measurement group_id="O3" value="NA">3 of 9 samples BLQ. Another subject did not have PK sampling past 48 hours. 5 values were reportable (5 of 9 = total N of 55.6%), no descriptive statistics calculated. A total N of 66.7 % (2/3) of reportable values is needed.</measurement>
                    <measurement group_id="O4" value="36.2" spread="272.0"/>
                    <measurement group_id="O5" value="56.2" spread="186.0"/>
                    <measurement group_id="O6" value="NA">3 of 9 samples BLQ and another sample excluded, no descriptive statistics calculated</measurement>
                    <measurement group_id="O7" value="20.1" spread="175.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Clinically Significant Changes in Vital Signs (Pulse Rate, Systolic and Diastolic Blood Pressure).</title>
        <description>Number of patients with clinically significant changes in vital signs (pulse rate, systolic and diastolic blood pressure) presents the number of patients with an reported adverse event which has a symptom in changes in vital signs. Vascular disorders was identified as changes in vital signs. The number of participant with vascular disorders is presented in this outcome measure</description>
        <time_frame>Baseline, up to day 14</time_frame>
        <population>The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Fibrosis</title>
            <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O8">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Clinically Significant Changes in Vital Signs (Pulse Rate, Systolic and Diastolic Blood Pressure).</title>
          <description>Number of patients with clinically significant changes in vital signs (pulse rate, systolic and diastolic blood pressure) presents the number of patients with an reported adverse event which has a symptom in changes in vital signs. Vascular disorders was identified as changes in vital signs. The number of participant with vascular disorders is presented in this outcome measure</description>
          <population>The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Abnormal Findings in 12-lead ECG (Electrocardiogram)</title>
        <description>Number of patients with a new onset of an abnormal finding by central assessment are presented.</description>
        <time_frame>up to 14 days</time_frame>
        <population>Treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation. Only patients included having no missing ECG measurements .</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Fibrosis</title>
            <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Abnormal Findings in 12-lead ECG (Electrocardiogram)</title>
          <description>Number of patients with a new onset of an abnormal finding by central assessment are presented.</description>
          <population>Treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation. Only patients included having no missing ECG measurements .</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus rhythm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morphology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ST segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-wave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U-wave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Abnormal Changes in Laboratory Tests</title>
        <description>Number of patients with abnormal changes in safety laboratory tests including urine protein diagnostics, and adrenocorticotropic hormone (ACTH) and cortisol measurements resulted in adverse events.</description>
        <time_frame>Baseline, up to day 14</time_frame>
        <population>The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Fibrosis</title>
            <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O8">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Abnormal Changes in Laboratory Tests</title>
          <description>Number of patients with abnormal changes in safety laboratory tests including urine protein diagnostics, and adrenocorticotropic hormone (ACTH) and cortisol measurements resulted in adverse events.</description>
          <population>The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <description>Number of patients with any adverse event (AE)</description>
        <time_frame>up to 14 days</time_frame>
        <population>The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Fibrosis</title>
            <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O8">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <description>Number of patients with any adverse event (AE)</description>
          <population>The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Abnormal Findings in Physical Examination</title>
        <description>The number of patients with abnormal findings in physical examination presents the number of patients with any treatment-emergent adverse events in this study.</description>
        <time_frame>up to day 14</time_frame>
        <population>The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Fibrosis</title>
            <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg Fibrosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O5">
            <title>DBV 400mg Cirrhosis</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O8">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Abnormal Findings in Physical Examination</title>
          <description>The number of patients with abnormal findings in physical examination presents the number of patients with any treatment-emergent adverse events in this study.</description>
          <population>The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Global Tolerability on a 4-point Scale</title>
        <description>The global tolerability was presented on a four item scale: good, satisfactory, not satisfactory and bad. Rating was done by the investigator.</description>
        <time_frame>day 6</time_frame>
        <population>The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Fibrosis</title>
            <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days. Subgroup of patients in fibrosis and in cirrhosis presented in one arm.</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Global Tolerability on a 4-point Scale</title>
          <description>The global tolerability was presented on a four item scale: good, satisfactory, not satisfactory and bad. Rating was done by the investigator.</description>
          <population>The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Temperature</title>
        <description>The body temperature will be presented as the mean values in visit 1 and visit 7. The number of participants analysed displays the number of participants included in the analysis set whereas the numbers for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Visit 1, Visit 7</time_frame>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Fibrosis</title>
            <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O2">
            <title>DBV 100mg Fibrosis</title>
            <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O3">
            <title>DBV 200mg Fibrosis</title>
            <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O4">
            <title>DBV 400mg</title>
            <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days. Subgroup of patients in fibrosis and in cirrhosis presented in one arm.</description>
          </group>
          <group group_id="O5">
            <title>DBV 600mg Cirrhosis</title>
            <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
          </group>
          <group group_id="O6">
            <title>DBV 800mg Fibrosis</title>
            <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
          <group group_id="O7">
            <title>DBV 1200mg Fibrosis</title>
            <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature</title>
          <description>The body temperature will be presented as the mean values in visit 1 and visit 7. The number of participants analysed displays the number of participants included in the analysis set whereas the numbers for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>Treated set.</population>
          <units>degree (°C)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (N=7/5/8/14/5/7/6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.429" spread="0.287"/>
                    <measurement group_id="O2" value="36.780" spread="0.455"/>
                    <measurement group_id="O3" value="36.513" spread="0.557"/>
                    <measurement group_id="O4" value="36.550" spread="0.641"/>
                    <measurement group_id="O5" value="35.760" spread="0.709"/>
                    <measurement group_id="O6" value="36.686" spread="0.248"/>
                    <measurement group_id="O7" value="36.517" spread="0.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (N=13/9/9/15/5/8/10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.400" spread="0.283"/>
                    <measurement group_id="O2" value="36.656" spread="0.403"/>
                    <measurement group_id="O3" value="36.156" spread="0.265"/>
                    <measurement group_id="O4" value="36.307" spread="0.451"/>
                    <measurement group_id="O5" value="35.540" spread="0.445"/>
                    <measurement group_id="O6" value="36.125" spread="0.287"/>
                    <measurement group_id="O7" value="36.320" spread="0.744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessment of adverse events from the baseline up to 14 days</time_frame>
      <desc>The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomisation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Fibrosis</title>
          <description>Placebo (as tablet, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="E2">
          <title>DBV 100mg Fibrosis</title>
          <description>DBV 100mg (as tablet, 2x 50mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="E3">
          <title>DBV 200mg Fibrosis</title>
          <description>DBV 200mg (as tablet, 1x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="E4">
          <title>DBV 400mg Fibrosis</title>
          <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="E5">
          <title>DBV 400mg Cirrhosis</title>
          <description>DBV 400mg (as tablet, 2x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
        </group>
        <group group_id="E6">
          <title>DBV 600mg Cirrhosis</title>
          <description>DBV 600mg (as tablet, 3x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with cirrhosis</description>
        </group>
        <group group_id="E7">
          <title>DBV 800mg Fibrosis</title>
          <description>DBV 800mg (as tablet, 4x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
        <group group_id="E8">
          <title>DBV 1200mg Fibrosis</title>
          <description>DBV 1200mg (as tablet, 6x 200mg, oral) administered 3 times (every 8 hours) daily after a meal for 5 days in patients with fibrosis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Faeces pale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lip disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urine colour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

